Тромботические осложнения у детей с неходжкинскими лимфомами
https://doi.org/10.17650/1818-8346-2013-8-2-41-46
Аннотация
Целью работы явилось выявление факторов риска развития венозного тромбоза (ВТ) у детей с неходжкинскими лимфомами (НХЛ). Эпизоды ВТ были выявлены у 13 из 174 пролеченных детей, т. е. частота ВТ составила 7,5 %. В работе проанализировано возможное влияние таких признаков, как морфологический вариант заболевания, инициальное поражение средостения, пол, возраст, применение L-аспарагиназы в лечебных протоколах, в качестве факторов, предрасполагающих к развитию тромбоза.
Результатами многофакторного анализа подтверждена роль первичной медиастинальной локализации опухоли (OR = 4,73 (CI: 1,42–17,10)) и возраста пациента старше 13 лет в качестве независимых прогностических факторов риска развития тромбоза у детей с НХЛ (OR = 4,3 (CI: 1,19–20,28)), р < 0,05.
Об авторах
Н. В. ЛипайРоссия
А. С. Фёдорова
Россия
В. В. Дмитриев
Россия
Список литературы
1. Lee A., Levine M. Venous thromboembolism and cancer: risk and outcomes. Circulation 2003;107:17–21.
2. Lip G.Y., Chin B.S., Blann A.D. Cancer and prothrombotic state. Lancet Oncol 2002;3(1):27–34.
3. Athale U.H., Chan A. Thrombosis in children with acute lymphoblastic leukemia. Part II. Pathogenesis of thrombosis in children with acute lymphoblastic leukemia: effects of the disease and therapy. Thromb Res 2003;111:199–212.
4. Garth B., Lloyd D. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol 2004;77:331–5.
5. Zakarija A., Kwaan H.C. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost 2007;33:355–64.
6. Khorana A.A., Francis C.W., Culakova E. et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5(3):632–4.
7. Kwaan H.C., Vicuna B. Incidence and pathogenesis of thrombosis in hematologic malignances. Semin Thromb Hemost 2007;33(4):303–12.
8. Caruso V., Di Castelnuovo A., Meschengieser S. et al. Thrombotic complications in patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events.Blood 2010;115:5322–8.
9. Athale U.H., Chan A.K. Thromboembolic complications in pediatric patients with hematologic malignancies. Semin Thromb Hemost 2007;33(4):416–26.
10. Athale U.H., Siciliano S., Thabane L. et al. Epidemiology and clinical risk factors predisposing to thromboembolism in children with cancer. Pediatr Blood Cancer 2008;51(6):792–7.
11. Mitchell L.G. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-Asparaginase. Cancer 2003;97(2):508–16.
12. Mitchell L.G., Lambers M., Flege S. et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a
13. multicentral cohort study. Blood 2010;115(24):4999–5004.
14. Swerdlow S.H., Campo E., Harris N.L. et al. WHO Classification of Tumours, Volume 2; IARC WHO Classification of Tumours, No 2. Lyon,France, IARC Press, 2008. 439 p.
15. Murphy S.B. Classification, staging and end results of treatment of childhood non- Hodgkins lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1990;7:332–8.
16. Cazals-Hatem D., Lepage E., Brice P. et al. Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (“Groupe d'Etude des Lymphomas de l'Adulte”) study. Am J Surg Pathol 1996;20(7):877–88.
17. Lipay N.V., Dmitriev V.V., Borisenok M.B. Thrombotic complications during cancer treatment in children. Exp Oncol 2007;29(3):31–5.
18. Khorana A.A., Francis C.W., Culakova E. et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 2006;24:484–90.
19. Athale U.H., Nagel K., Khan A.A., Chan A.K.C. Thromboembolism in children with lymphoma. Thromb Res 2008;122:459–65.
20. Blom J.W., Doggen C.J., Osanto S., Rosendaal F.R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293(6): 715–22.
21. Pusterla S., Previtali S., Marziali S. et al. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J 2004;5(4):341–6.
Рецензия
Для цитирования:
Липай Н.В., Фёдорова А.С., Дмитриев В.В. Тромботические осложнения у детей с неходжкинскими лимфомами. Онкогематология. 2013;8(2):41-46. https://doi.org/10.17650/1818-8346-2013-8-2-41-46
For citation:
Lipay N.V., Fedorova A.S., Dmitriev V.V. Thrombotic complications in children with non-Hodgkin lymphoma. Oncohematology. 2013;8(2):41-46. (In Russ.) https://doi.org/10.17650/1818-8346-2013-8-2-41-46